In the March 27, 2015, Federal Register, FDA announced the reclassification of the brain injury adjunctive interpretive electroencephalograph assessment aid into Class II (special controls). FDA is requiring certain labeling, software verification and validation, and biocompatibility assessments to mitigate identified health risks, such as adverse tissue reaction and equipment malfunction leading to injury.
The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.
